转移性结直肠癌靶向治疗的文献计量及可视化分析  

Bibliometric and visual analysis of targeted therapy for metastatic colorectal cancer

作　　者：杨雨 李俊洋 张艮龙 YANG Yu;LI Junyang;ZHANG Genlong(Fifth Department of General Surgery,Suzhou Municipal Hospital Affiliated to Anhui Medical University,Suzhou,Anhui 234000,China)

机构地区：[1]安徽医科大学附属宿州市立医院普外五科,安徽宿州234000

出　　处：《医药前沿》2025年第12期1-6,共6页Journal of Frontiers of Medicine

摘　　要：目的揭示转移性结直肠癌(mCRC)靶向治疗领域的研究热点分布情况,并进一步推测该领域未来的发展趋势。方法使用Web of Science核心数据集(WOSCC)科学引文索引拓展版(SCIE)的主题检索式检索2005年1月—2024年11月有关mCRC靶向治疗的相关文献,并在CiteSpace、VOSviewer和Charticulator中进行文献计量学及可视化分析。结果共纳入1365篇文献,2005—2024年mCRC靶向治疗研究领域的年发文量总体呈增长趋势,未来该领域发文量将持续增加。发文量和总被引频次最多的国家(地区)均是美国。发文最多的期刊是Clinical Colorectal Cancer;共被引次数最多的期刊是Journal of Clinical Oncology。关键词分析显示研究热点主要集中在耐药性克服、联合化疗应用及相关预后、临床试验与药物开发、针对Kirsten大鼠肉瘤病毒癌基因同源物(KRAS)基因突变和微卫星不稳定性(MSI)患者的一线治疗策略以及生长因子受体靶向药物。关键词生长因子受体的突现强度最高。未来FOLFIRI方案加贝伐珠单抗、循环肿瘤基因(ctDNA)、FOLFOXIRI方案加贝伐珠单抗、生存和分子亚型等相关研究可能成为研究热点。结论mCRC靶向治疗的研究热度逐年上升,研究热点集中于耐药性克服、联合化疗应用及相关预后、临床试验与药物开发、针对KRAS基因突变和MSI患者的一线治疗策略以及生长因子受体靶向药物。Objective To reveal the distribution of research hotspots in the field of targeted therapy for metastatic colorectal cancer(mCRC)and further predict future development trends in this field.Methods Relevant literature on targeted therapy for mCRC from January 1,2005 to November 25,2024 was retrieved using the Web of Science Core Collection(WOSCC)Science Citation Index Expanded(SCIE)database with topic search formulas.Bibliometric and visual analyses were conducted using CiteSpace,VOSviewer,and Charticulator.Results A total of 1365 articles were included.The annual publication volume in the field of targeted therapy for mCRC from 2005 to 2024 showed an overall increasing trend,and future publication volume in this field is expected to continue growing.The United States had the highest number of publications and total citations.The journal with the most publications was Clinical Colorectal Cancer,the most frequently cited journal was Journal of Clinical Oncology.Keyword analysis revealed that research hotspots mainly focused on overcoming drug resistance,combined chemotherapy,clinical trials and new drug development,first-line treatment strategies for patients with kirsten rat sarcoma viral oncogene homolog(KRAS)mutations and microsatellite instability(MSI),and growth factor receptor targeted drugs.The key word growth factor receptor had the highest burst strength.Future research hotspots may include studies on the FOLFIRI regimen plus bevacizumab,circulating tumor DNA(ctDNA),the FOLFOXIRI regimen plus bevacizumab,survival,and molecular subtypes of mutant genes.Conclusions Research interest in targeted therapy for mCRC is increasing annually,with hotspots focusing on overcoming drug resistance,combination chemotherapy,clinical trials for new drugs,treatment strategies for KRAS/MSI patients,and growth factor receptor-targeted drugs.

关 键 词：转移性结直肠癌 靶向治疗 文献计量学 可视化分析 耐药性克服 生长因子受体 

分 类 号：R735[医药卫生—肿瘤]